Fresenius_Medical_Care
Pendapatan operasi | EUR €2,362 juta (2017)[1] |
---|---|
Industri | Penjagaan kesihatan |
Jumlah aset | EUR €24.025 bilion (end 2017)[1] |
Pendapatan bersih | EUR €1,280 juta (2017)[1] |
Bilangan pekerja | 114,000 (FTE, end 2017)[2] |
Perancang utama | Rice Powell (CEO and Chairman of the executive board), Michael Brosnan (CFO), Harry de Wit (Chief Executive Officer for Asia-Pacific), Katarzyna Mazur-Hofsaess, Ph.D. (Chief Executive Officer for Europe, Middle East and Africa), Kent Wanzek (Chief Executive Officer for Global Manufacturing and Quality), William Valle (Chief Executive Officer for North America), Dr. Olaf Schermeier (Chief Executive Officer for Global Research and Development), Dr. Dieter Schenk (Chairman of the supervisory board) |
Jumlah ekuiti | EUR €10.828 bilion (end 2017)[1] |
Ibu pejabat | Bad Homburg, Jerman |
Laman sesawang | www.freseniusmedicalcare.com |
Keluaran | Produk dan perkhidmatan dialisis buah pinggang, Produk Apheresis Terapeutik |
Ditubuhkan | 1996 |
Hasil | EUR €17.7 bilion (2017)[1] |
Didagangkan sebagai | FWB: FME NYSE: FMS |
Jenis | Kommanditgesellschaft auf Aktien dengan Aktiengesellschaft as partner with unlimited liability |